Summary This study was designed to describe the course of epilepsy (in terms of seizure frequency) and to assess the variables (antiepileptic therapy regimens and others) correlated to improvement. Seizure frequency (categories: seizure free, more than one seizure/year, monthly seizures, weekly seizures and daily seizures) and antiepileptic medication were retrospectively compared between 1992 and 2002 in a large cohort of 550 inpatients with chronic epilepsy and different degrees of intellectual disability or multiple handicaps. Results: Seizure frequency decreased significantly ( p < 0.001). 218 of the 394 patients (55.3%) not seizure free in 1992 improved (changed into a better frequency category). The improvement rate was marginally higher in patients who had undergone a medication change ( p = 0.08). A high seizure frequency in 1992 ( p = 0.016) and older age ( p = 0.006), but not epilepsy syndrome or degree of intellectual disability, were predictors for improvement (stepwise logistic regression analysis).
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56.4% of the improved patients were on combinations of two AEDs (17.4%, monotherapy; 20.2%, triple therapy). The most frequent therapy regimens in the improved patients were lamotrigine/valproate (48 patients), carbamazepine/phenobarbital (21) and carbamazepine only (19). Lamotrigine/valproate was effective in all kinds of epileptic syndromes. Most patients on lamotrigine had serum concentrations above 10 mg/ml, approximately one half had dosages above 200 mg/day. The rate of seizure freedom increased from 28.4 to 37.6%. The 84% of the patients seizure free in 1992 remained seizure free. Predictors for seizure freedom in 2002 were higher age (stepwise logistic regression, p < 0.0005) and seizure freedom in 1992 ( p < 0.0005). Conclusions: Substantial improvement can be achieved even in intellectually disabled patients with chronic epilepsy. Although the rate of seizure freedom is reduced
Introduction
Epilepsies in the context of intellectual disability a (ID) are often characterised by a high seizure frequency and multiple seizure types. 1 Although it is well-known that they are difficult to treat or resistant to treatment in many cases more detailed information about the long-term course of epilepsy is scarce. In one of the rare longitudinal studies the rate of seizure free patients decreased from 71 to 58% over a 12 years period. 2 There is also a lack of information on the long-term impact of the new antiepileptic drugs (AEDs) in ID patients. While a number of studies have focussed on the responder rates and tolerability of single drugs, it is virtually unknown to what extent the ID population in general has benefited from innovative therapies.
The intention of this study was to assess the course of epilepsy (in terms of seizure frequency) over a period of 10 years as well as the impact of different antiepileptic drug regimens (classic and new AEDs) and other variables on seizure frequency in intellectually disabled patients with longstanding epilepsy.
During such a long period, antiepileptic therapy could have remained stable or have undergone numerous changes in different patients. There is no standardised way to follow such a diversity of therapies in all detail in a large number of patients. We therefore chose for the approach of two ''snapshots'', a comparison of the seizure frequencies and therapeutic regimens in the years 1992 and 2002.
Methods
We investigated retrospectively the inpatients of the residential department of the Bethel epilepsy centre which provides long-term care for patients with epilepsy and different degrees of intellectual and/or physical disabilities. While some of the older resident patients who were admitted decades ago have less severe epilepsy, the majority of the more recently admitted, mostly younger patients suffer from difficult-to-treat epilepsies. Our investigation was carried out in the whole main body of the organisation which is located in the city of Bielefeld. Only two residences which care for a different clientele were excluded. All residents in permanent residential care since 1992 or longer with a diagnosis of epilepsy were included. Study participants therefore have long-standing epilepsy with different degrees of severity as well as the whole spectre of intellectual and physical impairments (from borderline intelligence b to profoundly multi-handicapped).
Long-term antiepileptic treatment has been carried out by a team of neurologists and psychiatrists with special interest and experience in the diagnosis and treatment of epilepsy. Therapy has reflected normal clinical practice with no formal protocol followed but adhering to acknowledged principles: to achieve seizure freedom whenever possible; if this was not possible, to reach a maximum reduction in seizure frequency and severity; to strive for the patients' best possible quality of life through a balance between seizure control and side effects; to limit the number of AEDs prescribed in the individual patient to the minimum needed; to respect the expressed wishes of the patients or their legal representatives. Patients were seen and drug therapy was reviewed in regular intervals (approximately every 2 weeks to every 3 months) according to clinical needs.
In 2003, a data sheet was filled in by the authors on all patients included. Data extracted from the individual case histories and from the current case documentation included seizure frequency and antiepileptic medication in 1992 and 2002, the diagnosis of epileptic syndrome (based on seizure descriptions and EEG findings, according to the International League Against Epilepsy classification 3 ) , and degree of learning disability. Seizure frequency was subdivided into the following categories: completely seizure free; nearly seizure free (compatible with one uncomplicated seizure during the whole year or with one or two seizures due to acute disease or forgotten medication or with isolated auras); more than one seizure/year; more than one seizure/month; a The terms intellectual disability and learning disability are used synonymously in this text. more than one seizure/week; more than one seizure/day. If antiepileptic medication had not been stable throughout the whole year 1992 or 2002, certain rules were applied to choose the key date within the year (longest period of time with stable medication; day when a [trough] serum level was determined; if more than one trough serum level had been determined: the latest).
Changes in seizure frequency were evaluated as follows: patients who changed into a better category from 1992 to 2002 will be referred to as ''improved'', those who changed into the next better category but one (or more) will be called ''strongly improved''. For example, if a patient with weekly seizures in 1992 had more than one seizure/month in 2002, he was ''improved'', if he had only more than one seizure/ year in 2002, he was ''strongly improved''. Patients who remained in the same category were ''unchanged'', patients in a category with higher seizure frequency ''worsened''. Nearly seizure free and completely seizure free were evaluated as one common category. With this method, only substantial changes of seizure frequency were covered.
Out of 867 residents, 580 met the inclusion criteria. Twenty-five had to be excluded, 5 because the 1992 files were completely lacking, 20 for different reasons (insufficient data; epilepsy surgery carried out between 1992 and 2002, or because frequent additional psychogenic non-epileptic paroxysmal events made it impossible to determine the frequency of epileptic seizures). Five patients who developed epilepsy after 1992 were not included either. The remaining 550 patients formed the study cohort.
Results
For the characteristics of the 550 patients (male, 299; female, 251) see Table 1 .
There was a clear decrease in seizure frequencies from 1992 to 2002 (Wilcoxon test, p < 0.001). The number of patients with frequent (daily or weekly) seizures decreased considerably (Fig. 1) . The number of seizure free patients increased from 156 (121 completely, 35 nearly seizure free) to 207 (159 completely, 48 nearly seizure free). 218 patients had an improvement in seizure frequency. 275 patients remained unchanged while 57 worsened.
Further development of patients who were seizure free in 1992 131 out of the 156 patients (84.0%) seizure free in 1992 remained seizure free (Table 2 ). In 53 (40.5%) of these, antiepileptic therapy remained unchanged. In 52 (39.7%) of the 131 patients, some type of medication reduction had been carried out. In 21 cases, the dosage of one or more AEDs had been reduced. In 28 patients, one or more AEDs had been removed out of the original 1992 regimen (in 25 patients 1 AED, in 2 patients two AEDs, and in one patient 3 AEDs). AEDs most often involved in this were PB c (13 cases, +2 cases PRM), CBZ (9), and PHT (4). The most frequent change was from CBZ/PB to CBZ alone. In three patients, medication had been completely discontinued. In 23 of the 131 patients (17.6%), therapy had been altered (apart from the reductions already mentioned): 10 patients had a different regimen, 13 a substantial change in dosage or serum concentration.
25 (16.0%) of the formerly seizure free patients had again seizures in 2002, 15 patients had >1 seizure/year, 9 had >1 seizure/month, and one patient had >1 seizure/week (Table 2) .
Further development of patients who had seizures in 1992
218 of the 394 patients (55.3%) not seizure free in 1992 were improved in 2002. Fifty-nine (15.0%) of them were strongly improved. Table 2 gives details on the number of patients who changed from one seizure frequency category to another.
The improvement rate was marginally higher in patients who had undergone a medication change (197 improved of 347 whose medication was changed; 56.8%) than in those whose medication was unchanged (21 of 47 or 44.7% improved; p = 0.08, Fisher's exact test, one-sided).
Predictors for improvement
We assumed other factors besides AED changes could have influenced changes in seizure frequency.
The improvement rates in different degrees of ID, in different epileptic syndromes, in different age groups and according to seizure frequency in 1992 are shown in Table 3 .
Univariate analysis revealed that high improvement rates were correlated with a high seizure frequency in 1992 ( p = 0.017, test of trend, twosided) and weakly correlated with higher age ( p = 0.092, test of trend, two-sided). There was also a correlation between high seizure frequency in 1992 and a medication change ( p = 0.001, test of trend, two-sided). There was neither a significant correlation between epilepsy syndrome and improvement rate nor between degree of intellectual impairment and improvement rate (Table 3) .
Stepwise logistic regression analysis including epilepsy syndrome, age group, and seizure frequency in 1992, found only seizure frequency (OR = 1.474, d CI 95% 1.16-1.87, p = 0.016) and older age (OR = 1.24, CI 95% 1.06-1.44, p = 0.006) to be predictors for improvement.
Antiepileptic therapy of improved patients
38 of the improved patients (17.4%) were on monotherapy (CBZ: 19; VPA: 8; PB: 6; PHT: 3; LTG: 2).
More than a half (123; 56.4%) of the improved patients was on a combination of two AEDs. LTG/VPA (48; 17 of them strongly improved) and CBZ/PB (21; 5 of them strongly improved) were by far the most frequent out of a total of 24 different duotherapies (OCBZ/VPA: 9; CBZ/VPA: 7; PB/VPA: 6; PB/PHT: 5; all others: <5).
44 improved patients (20.2%) were on a combination of three AEDs (LTG/PB/VPA: 7; CBZ/LTG/ 38 B. Huber et al. VPA: 3; all others: <3). Altogether, there were 29 different triple combinations. Thirteen improved patients (6.0%) were on 13 different combinations of 4 AEDs. In total, there was a diversity of 71 different therapeutic regimens in the improved patients, but only a few of them are salient (Fig. 2) . Fig. 3 shows the therapeutic regimens which led to improvement in the different epilepsy syndromes. Fig. 4 gives details of LTG/VPA, the most important therapeutic regimen. The spectrum of LTG dosages and serum concentrations used was broad with a majority of serum concentrations above 10 and also above 15 mg/ml. In detail, the daily doses and serum concentrations (mean value AE standard deviation) in the 48 improved patients on LTG/VPA were: LTG 242.8 AE 99.2 mg; 14.2 AE 3.5 mg/ml; VPA 1796.9 AE 769.5 mg; 82.8 AE 24.5 mg/ml.
The daily doses and serum concentrations in the 21 improved patients on CBZ/PB were: CBZ 1378.6 AE 421.8 mg; 8.1 AE 2.5 mg/ml; PB 118.8 AE 39.7 mg; 21.7 AE 7.6 mg/ml.
The corresponding values in the 19 improved patients on CBZ monotherapy were: 1471.1 AE 517.0 mg; 10.8 AE 2.2 mg/ml.
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Discussion
A study like this has obvious limitations, mainly due to its retrospective character which, among others, did not allow including those patients who died or left the institution between 1992 and 2002. It is evident that results obtained in a selected population cannot plainly be generalised about an average epilepsy population. On the other hand, strengths are the quality of seizure documentation (seizure records accurately kept on every resident patient for decades) which appeared to be good in an organisation with a long tradition of epilepsy care, and the low rate of exclusions due to incomplete data. Another strong point is the large number of patients followed over a prolonged period of time.
It is well-known that the therapy prognosis in terms of seizure freedom is worse in ID patients than in a non-handicapped epilepsy population. For example, the proportions of seizure free patients in similar samples were 44.1, 4 27 5 and 43%, 6 as opposed to an expected approx. three quarters in an average epilepsy population. The rate of seizure freedom in our study (28.4% in 1992, 37.6% in 2002) is within this range. However, the number of new seizure free patients (76, or 19.3%) is surprisingly high in this selected and predominantly difficult-totreat sample. And what is more, the rate of 55.3% improved patients indicates that, even if complete seizure control may not be a realistic goal for the majority of these patients, substantial improvement in seizure frequency can be achieved through continual therapeutic trials. As Tables 2 and 3 have shown, especially a remarkable part of those with frequent seizures improved. In the epidemiological study by Forsgren 4 only a minority of patients had frequent seizures (32.1% yearly seizures, 12.6% monthly, 11.3% weekly, 2.7% daily seizures). This is in sharp contrast to the distribution of seizure frequencies in our study (mainly in 1992) which reflects the selected clientele of an epilepsy centre.
Our improvement rate of 55.3% is similar to that of a comparable study by Scheepers et al. 7 These authors achieved an improvement rate of 57% over a period of 2 years. However, their criterion (a 50% reduction in seizure frequency) was less strict than ours. In their study, most of the improvements were due to the introduction of LEV and LTG while the use of classic AEDs decreased. Opposite to these results, in the above mentioned study by Branford et al. 2 the rate of seizure freedom decreased from 1985 until 1997. At the same time, the use of polypharmacy increased. New AEDs (GBP, LTG and also VGB) were beginning to be used. An explanation for the deterioration given by the authors was a change in the care setting of many of these patients which may have led to a loss of specialist treatment. The lack of a correlation between seizure outcome and degree of ID is in accord with the results by Sillanpää 8 and Kelly. It would be a simplification to attribute the improvements seen in this population exclusively to AED changes and to ignore other variables such as the spontaneous course of the disease, the increase in age of our study population, additional psychosocial and other external factors. It is therefore no surprise that the correlation between medication change and improvement was only marginally significant. Statistical analysis revealed a high seizure frequency and also older age as predictors of improvement. The higher improvement rates in patients with frequent seizures might be interpreted, in statistical terms, as a regression to the mean which should be taken into account as a confounding factor. For older age it remains undetermined if the natural course of the disease was the decisive factor, or if a selection bias was confounding (younger patients admitted to the organisation may have more severe epilepsy than older patients).
Even though the rate of seizure freedom is generally lower in ID patients, our results indicate that once a patient is seizure free the prognosis as for constant seizure freedom is very good. This is in contrast to the findings by Sillanpää 8 who reported a higher relapse risk after 5 years of seizure freedom for patients with versus without learning disability. As ID and also neurological deficit are known risk factors for seizure relapse after terminating therapy 9 our approach towards seizure free patients has been cautious. Medication has frequently been simplified or reduced but only rarely completely discontinued in seizure free patients.
Monotherapy was still the domain of classic AEDs (mainly CBZ and VPA) in our study. We feel this was mainly a consequence of regulatory policies (introduction of new AEDs only for add on treatment, delayed approval for monotherapy). While monotherapy is considered the treatment of choice by many experts, AED combinations (mostly of two AEDs) count for a majority of the improvements in our study. One might conclude that in chronic epilepsy -as opposed to uncomplicated or newly diagnosed epilepsy -monotherapy is not sufficient for many patients. Other authors have pointed out that combination therapy does not necessarily lead to an increase in adverse effects. 10 LTG/VPA has been the therapy regimen most frequently used in improved and also in strongly improved patients (Fig. 2) . This is in accord with the opinion of some experts who believe the combination of LTG and VPA to be the quintessential example of rational combination therapy. 11 Our clinical experience suggests that this combination is also well tolerated by intellectually disabled patients. Our data on LTG indicate that the manufacturer's recommended daily dosage (100-200 mg/day in combination with VPA) may be much too low (Fig. 4) , at least in difficult-to-treat patients. They confirm the findings by Hirsch et al. 12 who also reported increasing efficacy of LTG in serum levels up to >20 mg/ml.
As no systematic comparison has been made between LTG/VPA and LTG or VPA alone, only cautious conclusions should be drawn from our results. But interestingly, in a similarly designed study 13 the combination LTG/VPA was also most successful, a fact which coincides with our findings. While most recommendations on how to combine AEDs are theory-based, e.g. to combine drugs of different modes of action, these results provide clinical support to the view that LTG/VPA is a major innovation of the last decade.
The therapy regimen most successful but one has been CBZ/PB (Fig. 2) suggesting that this combination of classic AEDs remains an effective therapeutic option. This combination had been used much more frequently in our organisation before the era of the new AEDs. Another successful duotherapy was OCBZ/VPA which may have replaced in part the traditional combination CBZ/VPA due to its metabolic advantages.
Our findings suggest that there is no major variation in improvement rates between the different epileptic syndromes (Table 3 ). Due to the uneven syndrome distribution it is also difficult to recognise differences in the improvement rates on the various therapy regimens with respect to epilepsy syndromes (Fig. 3) . LTG/VPA apparently is effective in all major forms of epilepsy. Only for CBZ (mainly alone but also in combination with PB) one might detect a lack of effect in LGS and symptomatic generalised epilepsy as compared to focal epilepsy. This corresponds with the well-known indication of CBZ which is mainly in focal epilepsy.
One might be surprised by the fact that after a decade during which more than half a dozen of new AEDs were introduced nearly as many improvements were achieved by optimisation of therapy with classic AEDs as by the use of new AEDs. The limited role of the new AEDs may be a question of time in the case of LEV which was introduced only in autumn of 2000, quite shortly before this investigation. For others it might be due to the experience of inefficacy (GBP) 14 or increased toxicity (TPM) 15 made in this population. The great proportion of classic AEDs in the improved patients could also be taken as a reminder not to neglect the classic AEDs despite the wave of new drugs.
Different studies have stressed the importance of seizure control for the patients' quality of life. 16 Personal experience with the course of treatment of many of the patients included, although not systematically documented, and also carers' feedback in a number of cases makes us believe that the reported improvements in seizure activity led to parallel improvements of quality of life in many of our patients. A formal assessment of this topic, unfortunately, was beyond the scope of this study.
We believe our knowledge on useful therapy regimens is only at the beginning, especially in the difficult-to-treat epilepsies of intellectually handicapped patients and further investigation in this field is needed.
